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Case 1
A 22-year-old Japanese woman presented with difﬁculty in walking
and numbness of her right thigh. Itwas revealed bymagnetic resonance
imaging (MRI) that she had a paravertebral tumor from the ﬁrst to third
lumbar vertebrae (Fig. 1A). A computed tomography (CT) scan showed
bilateral ovarian tumors (Fig. 1B). Paravertebral tumor resection was
performed immediately. Because the aim of surgery was spinal decom-Introduction
Neuroblastoma accounts for approximately 8–10% of all tumors in
children aged 15 years, and the incidence of neuroblastomas 1 in
7000 in the United States.
Neuroblastoma treatment is based on the clinical stage and catego-
ries. Surgery and/or chemotherapy are recommended. Most infants
with disseminateddisease have a favorable outcome after chemotherapy
and surgery, while themajority of children aged >18 months, who have
advanced neuroblastoma, die of progressive disease despite intensive
multimodality therapy.
Neuroblastomas develop from neural crest cells, and their ana-
tomical locations are essentially the adrenal glands and paraspinal
sites. Only a few reports of primary ovarian neuroblastoma have been
reported worldwide. Although it is commonly known that malignancy
occurs in 0.3–4.8% of mature cystic teratomas of the ovary (Mori et al.,
2003), neurobalstomas arising from mature cystic teratomas are
extremely rare, as we found only 4 cases published in the literature
since 1982 (Reid et al., 1983; Kleinman et al., 1993; Kiyozuka et al.,
1994; Muhlstein et al., 2010). Almost all ovarian neuroblastomas have
very poor prognoses; however, we performed intensive treatment
with a combination of surgery and chemotherapy and found no occur-
rence of relapse in two cases. Particularly, case 1 achieved complete
remission for >13 years in spite of multiple metastases., Nagoya, Aichi 466-8650, Japan.
.
Inc. Open access under CC BY license.pression, many tumors remained. Because her platelet count was low,
bone marrow aspiration was performed on the iliac crest, as metastasis
was suspected. Bone scintigraphy showed Th6, L1, L2, right ilium, left
femur, right rib metastases. The serum level of neuron speciﬁc enolase
(NSE) was 57 ng/mL, ferritin was 1520 ng/mL, and lactate dehydroge-
nase (LDH) was 1652 IU/L. Approximately 2 weeks after vertebra sur-
gery, we performed left salpingo-oophorectomy and right ovarian
tumor resection. These tumors were resectable.
Microscopically, two different tumor components were observed: a
neuroblastoma and a mature cystic teratoma (Fig. 1C), which were
connected. Therefore, we diagnosed this patient with primary ovarian
neuroblastoma. The right ovary revealed a mature cystic teratoma.
The serum levels of vanillylmandelic acid (VMA) and homovanillic
acid (HVA)were 1.0 and 1.3 mg/L, respectively.We began triweekly in-
travenous chemotherapy with a combination of etoposide (100 mg/m2
on days 1–5) and cisplatin (20 mg/m2on days1–5). A major complica-
tion was grade2 myelosuppression that was effectively managed with
granulocyte colony-stimulating factor (G-CSF). The residual tumors
disappeared as indicated by CT, MRI, and bone scintigraphy after com-
pletion of a course of 6 treatments. The serum levels of NSE, ferritin,
and LDH returned to normal, and, to date, no relapse has been observed
over a 13-year follow-up period.Case 2
A 25-year-old Japanese woman complained of abdominal bloating
and received a living donor (her mother) kidney transplant for chronic
renal failure due to renal hypoplasia when she was 13 years old. A
pelvic CT scan revealed a 120 × 115 × 125 mm mass (Fig. 2A). The
tumor markers were as follows: cancer antigen (CA)-125, 51 U/mL;
CA-72-4, 4.6 U/mL; and squamous cell carcinoma antigen,2.0 ng/mL.
Laparotomy was performed. It revealed that the patient's right ovary
was increased in size, although her uterus, fallopian tubes, and left
Fig. 1. Imaging and microscopic ﬁndings (case 1). A: Paravertebral tumor compressed spinal canal. B: Pelvic CT scan showed bilateral ovarian tumors. C: Histological diagnosis of
neuroblastoma (left side) and mature cystic teratoma (right side).
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vest of ascites was performed. We considered that there was no gross
residual disease. The patient's postoperative course was uneventful,
and the ﬁnal pathology report indicated neuroblastoma arising from a
mature cystic teratoma (Fig. 2C,D). Postoperative bone scintigraphy
was performed. It revealed no bone metastasis. Twenty-four-hour
urine samples were collected postoperatively. These samples showed
that theurinary excretion concentrations of VMAandHVAwere normal.
Ascites cytology was negative. Thus, we diagnosed InternationalFig. 2. Imaging and microscopic ﬁndings (case 2). A: Pelvic CT scan revealed a 120 × 115 ×
and mature cystic teratoma (left side). D: Neuroblastoma (high magniﬁcation).Federation of Gynecology and Obstetrics stage 1C(b) because of
intraoperative microrupture due to adhesion. Therefore, we adminis-
tered adjuvant chemotherapywith etoposide and cisplatin. Dose reduc-
tions were necessary to protect renal function. Thus, we decreased the
etoposide dose by 25% (75 mg/m2 on days 1–5) and cisplatin by 50%
(10 mg/m2on days 1–5) every 3 weeks. Her renal function was good,
and we used G-CSF to treat grade2 myelosuppression. She remained in
good healthwith no evidence of recurrence for 6 months after 6 courses
of chemotherapy.125 mm mass. B: Gross ﬁnding. C: Histological diagnosis of neuroblastoma (right side)
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Neuroblastomas can arise anywhere throughout the sympathetic
nervous system, although the adrenal glands are the most common
primary site. There have been only 9 cases of primary ovarian neuro-
blastoma reported worldwide since 1982 (Reid et al., 1983; Kleinman
et al., 1993; Kiyozuka et al., 1994; Muhlstein et al., 2010; Aguirre and
Scully, 1982; Block et al., 1984; Lawlor et al., 1997).
In our cases, the neuroblastomas likely arose from the neural tissue
of mature cystic teratomas. In the past reports, 4 of 9 cases were associ-
ated with mature cystic teratomas or immature teratomas, although
those with unclear origins have also been reported (Aguirre and
Scully, 1982; Block et al., 1984; Lawlor et al., 1997). Mature cystic tera-
toma shared 10–20% of its pathology with that of the benign ovarian
cyst and malignant change occurs in 0.3–4.8% (Mori et al., 2003).
Although most malignancies are due to squamous cell carcinomas,
changes in neuroblastomas are extremely rare.
Mori et al. (2003) reported that the average age of a patient with
malignant transformation is 54.7 years, which is 17 years older than
the average age of patients with mature cystic teratomas, whereas
Peterson (1957) reported an average age of 45.5 years. These data
suggest that malignant transformation may arise from mature cystic
teratomas after an average of 10 years. On the other hand, Kiyozuka
et al. (1994) reported that the average age of patients with primary
ovarian neuroblastomas was 23.4 years, which was younger than
those with common malignant transformations. Interestingly, neuro-
blastomas are common in infants and children, as the mean age at
diagnosis is 2 years, and 90% cases occur before the age of 5 years.
Malignant transformation to a neuroblastoma may occur earlier
than that to the other epithelial carcinomas.
The prognosis of primary ovarian neuroblastoma is unfavorable.
According to Muhlstein et al. (2010), in the 9 reported cases, including
4 malignant transformed teratoma cases, 4 patients died 2–7 months
after operation, 2 patients relapsed 11 and 24 months after operation,
and 3 patients achieved complete remission during the 7- to
24-month follow-up periods (Muhlstein et al., 2010). However, the
reported remissions have an insufﬁcient follow-up period, with a
maximum of 2 years. At the time of this report, our patient achieved
complete remission, which has been >13 years after diagnosis of a
primary tumor in spite of multiple metastases. Although the prognosis
of ovarian neuroblastoma is unfavorable, some patients achieve com-
plete remission in spite ofmultiplemetastases,which is similar to infant
neuroblastoma, as most infants with disseminated diseases have favor-
able outcomes following chemotherapy and surgery. The age at presen-
tation is an important prognostic factor in childhood neuroblastoma(London et al., 2005). Thus, we believe that in cases with good progno-
sis, ovarian neuroblastomas develop subsequently from pre-existing
mature cystic teratomas that arise in adults, whereas in cases with
bad prognosis, ovarian neuroblastomas develop gradually from mature
cystic teratomas.
Moreover, to investigate other factors in ovarian neuroblastoma,
including N-myc ampliﬁcation, DNA ploidy, and gain or loss of certain
chromosomes that are known as prognostic factors in childhood neu-
roblastoma cases, may offer new insight into the prognosis of ovarian
neuroblastoma. The treatment of primary ovarian neuroblastomas
has not received a consensus. Thus, we suggest intensive treatment
consisting of a combination of surgery and intravenous chemotherapy
of cisplatin (20 mg/m2 on days 1–5) and etoposide (100 mg/m2
on days 1–5) once every 3 weeks for a total of 6 courses. As a
treatment basis, Kiyozuka et al. (1994) reported this same regimen
and recommended these agents as key drugs against childhood neuro-
blastoma. Dose reduction was necessary to protect renal function in
case 2, and there was no major side effects, except for grade 2
myelosuppression in both patients, who are alive and present no
evidence of relapse. Speciﬁcally, the patient in case 1 has maintained
complete remission for >13 years in spite of multiple metastases.
This is the ﬁrst report to describe the use of surgical resection
combined with multiagent chemotherapy in ovarian neuroblastoma.
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